Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha(University of Ottawa), Jean‐Simon Diallo(University of Ottawa)Nature CommunicationsAugust 23, 202410.1038/s41467-024-51498-0Cited by 14SaveCiteExport RISWatch citationsRelated PapersPevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy|Molecular Therapy|2023|23The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy|Communications Biology|2020|16Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus|Frontiers in Immunology|2023|11